Discovery of benzodiazepine derivatives as a new class of covalent inhibitors of SARS-CoV–2 main protease
Bioorganic & Medicinal Chemistry Letters · 2023
DOI: 10.1016/j.bmcl.2023.129407 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2023. Verfasst von Falu Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Benzodiazepines, COVID-19, Protease Inhibitors, Coronavirus 3C Proteases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Sichuan University.
Abstract (Originalsprache)
The COVID-19 pandemic has caused people immense suffering all over the world. Although the World Health Organization (WHO) has announced the end of the pandemic, the sporadic virus epidemic is still ongoing and may exist permanently. Effective antivirals against SARS-CoV-2 are important to deal with the long-term threat. The main protease (Mpro) is a crucial target for drug development due to its role in the process of virus's replication and transcription. Herein, we report benzodiazepine derivatives as a new class of Mpro inhibitors. Structure-activity relationship (SAR) studies led to the discovery of the most active compound, methyl 10-(2-chloroacetyl)-1-oxo-11-(4-(trifluoromethyl)phenyl)-2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]-diazepine-7-carboxylate (11a), which shows an IC50 value of 0.180 ± 0.004 μM. The X-ray crystal structure shows that 11a covalently binds to Mpro. Collectively, we have obtained a new small molecule inhibitor targeting Mpro, which can serve as a lead compound for subsequent drug discovery against SARS-CoV-2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China; Department of Ophthalmology and Research Laboratory of Macular Disease, Wes…
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: leijian@scu.edu.cn.
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China; Frontier Medical Center, Tianfu Jincheng Laboratory, Chengdu, Sichuan 61021…
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Sichuan University
- National Postdoctoral Program for Innovative Talents
Zitieren
APA
Wang, F., Zeng, R., Qiao, J., Xia, A., Li, Y., Li, F., Wu, Y., Liu, Y., Zhao, X., Lei, J., & Yang, S. (2023). Discovery of benzodiazepine derivatives as a new class of covalent inhibitors of SARS-CoV–2 main protease. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2023.129407
Vancouver
Wang F, Zeng R, Qiao J, Xia A, Li Y, Li F, et al. Discovery of benzodiazepine derivatives as a new class of covalent inhibitors of SARS-CoV–2 main protease. Bioorganic & Medicinal Chemistry Letters. 2023. doi:10.1016/j.bmcl.2023.129407
BibTeX
@article{Wang2023,
author = {Wang, Falu and Zeng, Rui and Qiao, Jingxin and Xia, Anjie and Li, Yueshan and Li, Feng and Wu, Yunjie and Liu, Yuanzhi and Zhao, Xiu and Lei, Jian and Yang, Shengyong},
title = {Discovery of benzodiazepine derivatives as a new class of covalent inhibitors of SARS-CoV–2 main protease},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2023},
doi = {10.1016/j.bmcl.2023.129407}
}
EUVIMED